“It’s electricity-free, non-toxic, reusable - and you recharge it with just a coffee mug’s worth of water,” Tiffany Yeh unveils Eztia's cost-effective solution to overheating - common reagents.
From ship engines to smart batteries, 190-year-old Wärtsilä has reinvented itself as an energy storage powerhouse with lightning-fast speeds.
With over 25 years in digital transformation, Victor AbouRahal is setting his sights on wringing out wasted water costs.
“The energy transition isn’t just my job—it’s what drives me,” How Sonia St-Arnaud is tackling one of the biggest challenges in clean power.
A digital community for clothing repairs has high hopes to upskill consumers worldwide and trigger an upcycle revolution.
Peter DeYoung lends insights on the strategic approach behind Piramal Phama’s expansion and growth.
Shashi Shankar explains how his app unifies patients' scattered medical records all together, and what that has to do with the 21st Century Cures Act.
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
"Think of us as a critical partner in the ecosystem, ensuring that brilliant innovation doesn’t get stuck in the development phase but actually reaches the patients who need them."
Neil Warma explains how Mongoose Bio is pioneering TCR-T therapies that may last longer, tackle more cancers, and require less from patients.
Harnessing Nobel Prize-winning insights on telomeres, Geron’s CEO Dr. John A. Scarlett is taking on some of hematology’s toughest challenges—and winning FDA backing in the process.
“Almost all of the data that we use comes from our own laboratories - data generation doing real experiments in human biology… The AI side of things will be commoditized eventually, and the winners will be those who have the strongest data moat in life sciences.”
A Grammy-winning CEO is taking gene therapy to new heights.
Sinaptica's precision neuromodulation combines TMS and EEG to target memory networks, offering new hope in Alzheimer's care.
As clinical trials progress, Pendulum hopes their medical evidence can beat the status quo and encourage Americans to take preventative care into their own hands.
A recent multi-billion dollar deal with Novo Nordisk in diabetes and obesity, and an injection of significant funding through a $200 million government partnership - Aspect is worth watching as they enter 2025.
